Open AccessLow Abundance of Circulating Tumor DNA in Localized Prostate Cancer
Author(s) -
S. Thomas Hennigan,
Shana Y. Trostel,
Nicholas T. Terrigino,
Olga Voznesensky,
Rachel Schaefer,
Nichelle C. Whitlock,
Scott Wilkinson,
Nicole V. Carrabba,
Rayann Atway,
Steven Shema,
Ross Lake,
Amalia Sweet,
David J. Einstein,
Fatima Karzai,
James L. Gulley,
Peter Chang,
Glenn J. Bubley,
Steven P. Balk,
Huihui Ye,
Adam G. Sowalsky
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.19.00176
Subject(s) - prostate cancer , prostate , cancer , medicine , cell free fetal dna , pca3 , disease , oncology , somatic cell , localized disease , cancer research , dna sequencing , dna , gene , biology , genetics , pregnancy , fetus , prenatal diagnosis
Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies for detection of clinically significant disease before treatment. We hypothesized that patients with detectable circulating tumor DNA (ctDNA) were more likely to harbor aggressive disease.